Constellation Brands — Key Risks
Nearly All Revenue Comes From Mexican Beer — And That Concentration Is a Real Vulnerability
Constellation's Mexican beer brands (Corona, Modelo, Pacifico) represent the vast majority of its business. If consumer tastes shift, health trends accelerate (think GLP-1 weight-loss drugs reducing alcohol intake), or anything disrupts demand specifically for these brands, there is very little elsewhere in the portfolio to cushion the blow.
Tariffs on Mexican Imports Could Directly Raise Costs and Disrupt Operations
All of Constellation's beer is brewed in Mexico and shipped to the U.S. New or increased U.S. tariffs on Mexican imports — which the filing notes were imposed in April 2025 — could raise costs significantly. Because the company cannot easily move production out of Mexico on short notice, it has limited ability to dodge this risk quickly.
Almost All Beer Production Depends on a Small Number of Mexican Facilities With No Easy Backup
Every bottle of Corona and Modelo sold in the U.S. comes from Constellation's Mexican breweries. A disruption there — whether from severe weather, labor action, border closure, or equipment failure — could halt sales with no realistic short-term alternative. The filing also notes that one joint-venture glass plant supplies the majority of glass bottles for these brands, adding another single point of failure.
One Wholesaler Accounts for a Quarter of Total Company Sales
Constellation relies on a single wholesaler network that represents one-quarter of its consolidated net sales for beer. If that relationship sours, the wholesaler underperforms, or a labor dispute hits, a significant chunk of revenue could be disrupted almost immediately.
Billions in Brewery Expansion Spending Could Underdeliver
Constellation is in the middle of multi-billion-dollar brewery construction and expansion projects in Mexico. These carry real risks: cost overruns, permitting delays, and the possibility that new capacity arrives just as demand softens — leaving the company with expensive idle assets and a heavier debt load.
The Canopy Cannabis Investment Has Already Cost Billions and Remains a Drag
Constellation made a large bet on Canopy Growth, a Canadian cannabis company, which has resulted in significant impairment losses already. The investment continues to carry uncertainty, and the company's main credit facility restricts how it can interact with Canopy financially, limiting flexibility.
Active Securities Lawsuits Filed Against the Company in Early 2025
In February 2025, shareholders filed a class action lawsuit alleging that Constellation made misleading statements about its Wine and Spirits business strategy. Two derivative suits followed in March and April 2025. While the outcome is uncertain, defending these cases will cost money and management attention regardless.
Significant Debt Load Limits Financial Flexibility
Constellation has taken on substantial debt to fund acquisitions, brewery construction, dividends, and share buybacks. In a higher-interest-rate environment, debt service consumes a meaningful portion of cash flow — reducing the company's ability to invest, respond to downturns, or weather unexpected shocks without risking a credit rating downgrade.